"United in Heart, Advancing Together": NeuViva Medical and JiuTong Medical Sign Strategic Cooperation Agreement

NewMed is a high-tech medical innovation enterprise with independent intellectual property rights. It continuously conducts scientific and technological innovation and technical breakthroughs in the field of cardiovascular implants and interventions, focusing on the research, development, and industrialization of interventional artificial heart valves and interventional heart failure treatment devices. With the mission of "Innovation for the Benefit of Life," the group is committed to building a high-end medical device enterprise that belongs to China and is aligned with international standards.

Shanghai Jiutong Medical Technology Co., Ltd. focuses on the high-value consumables and equipment sector within the pan-vascular field. Leveraging its nationwide channel resources and customer base, the company provides platform-based diversified vertical services to innovative medical device products in the early R&D stage or rapid growth phase. These services include sales integration outsourcing, clinical research services, surgical technical support, channel management, and product brand operations. By focusing on growth enterprises, nurturing high-potential products, offering integrated solutions, and building specialized capabilities, Jiutong Medical is committed to establishing a one-stop marketing service platform for the pan-vascular field in the Chinese medical market.

The Prizvalve valve system, independently developed by NewMed over many years, was approved for marketing by the China National Medical Products Administration (NMPA) in 2024. It has become the first domestically produced balloon-expandable valve to be launched in China, filling the technical gap in the domestic market for Chinese-produced balloon-expandable valves and ushering in a new era of balloon-expandable valve interventional treatment for valvular heart disease. The product has applied for dozens of national patents and received support from the Shanghai Science and Technology Commission's key R&D program.

As the first domestically produced balloon-expandable transcatheter aortic valve product in China to enter the registration clinical study, the Prizvalve valve system aligns with the latest generation of international balloon-expansion valve technology. To make the product more suitable for the pathological and physiological anatomical structure of Chinese patients, it adopts a short stent design with balloon expansion. Innovations have been made in multiple aspects such as the valve frame, valve skirt, and delivery system.

Due to the design advantages of balloon-expandable valves, there have been numerous international reports on their clinical application in all four heart valves. To date, NewMed's balloon-expandable valve, Prizvalve, has enabled Chinese clinical experts to apply it across all four heart valves with comprehensive "heart" applications. It also supports the compatible clinical use of various devices (surgical valves, interventional valves, annuloplasty rings, stents), providing a domestically produced solution for the treatment of valvular diseases in China that keeps pace with international standards.